Sanara Ventures

Sanara Capital emerged in 2023 as a specialized Health-Tech investment fund, concentrating its resources on the rapidly evolving sectors of Digital Health, Bio-Convergence, and Medical Devices. The fund strategically positions itself to support Israeli-related startups at critical growth stages, specifically targeting Series A and B financing rounds for companies operating both within Israel and internationally. With its targeted approach to healthcare innovation, Sanara Capital represents a significant new player in the medical technology investment landscape.

Building upon the foundation established by its predecessor, Sanara Capital continues the legacy of Sanara Ventures, a seed-stage investment platform launched in 2015 with the backing of healthcare industry giants Philips and Teva. This strategic partnership with two global leaders in pharmaceuticals and medical technology provides Sanara with unparalleled industry insights, technical expertise, and valuable market access that benefits its portfolio companies. The combined ecosystem of both funds now nurtures nearly 20 active portfolio companies, creating a comprehensive support network spanning from early-stage to growth-phase ventures.

The investment strategy of Sanara Capital reflects a deep understanding of the unique challenges and opportunities within the Israeli health technology ecosystem. By focusing on companies with Israeli connections, the fund leverages the country's reputation as a global innovation hub, particularly in medical technology and life sciences. Their portfolio demonstrates a commitment to technologies that address significant healthcare challenges through novel approaches in digital solutions, the integration of biology with engineering disciplines, and innovative medical device development. This specialized focus allows Sanara to provide not just financial support but also domain-specific guidance to its portfolio companies.

As a growth-stage investor, Sanara Capital plays a crucial role in bridging the funding gap that often challenges promising healthcare startups as they move beyond initial product development toward market expansion and commercial scaling. The fund's experience with both Israeli and international markets positions it uniquely to help portfolio companies navigate regulatory pathways, establish strategic partnerships, and access global markets. By maintaining close relationships with industry leaders through its corporate backers and focusing on transformative healthcare technologies, Sanara Capital aims to accelerate innovations that can meaningfully impact patient care while generating substantial returns for investors.